C16orf78: A Potential Drug Target and Biomarker for Chromosome 16 Open Reading Frame 78

Target Name: C16orf78

NCBI ID: G123970

C16orf78

Other Name(s): chromosome 16 open reading frame 78 | Chromosome 16 open reading frame 78 | Uncharacterized protein C16orf78 | CP078_HUMAN

C16orf78: A Potential Drug Target and Biomarker for Chromosome 16 Open Reading Frame 78

Chromosome 16 (16p) is one of the human chromosomes, which contain around 2,900 protein genes. It is home to many genes that encode proteins involved in various cellular processes, including growth, development, and reproduction. Chromosome 16 also includes a region known as the open reading frame (ORF) 78, which contains a unique gene locus that is highly conserved across various species.

Recent studies have identified C16orf78, a gene located within the ORF 78 region of chromosome 16, as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will provide a comprehensive overview of C16orf78, including its function, potential drug targets, and potential as a biomarker.

Function of C16orf78

C16orf78 is a gene that encodes a protein known as C16orf78, which is a 21-kDa protein that contains a unique farnesylated cysteine residue. C16orf78 plays a crucial role in the regulation of cellular processes, including cell growth, apoptosis, and autophagy.

The C16orf78 gene is located within the ORF 78 region of chromosome 16 and has a calculated gene length of 1,854 base pairs (bases). The ORF 78 region of chromosome 16 is a highly conserved region that contains multiple gene loci, including C16orf78.

Potential Drug Targets

C16orf78 has been identified as a potential drug target due to its unique farnesylated cysteine residue, which is a key structural feature that can interact with various drug molecules. The cysteine residue is also known as a potential drug target for inhibiting the activity of histone-modifying enzymes, which are involved in the regulation of gene expression.

Several studies have identified potential small molecule inhibitors that can interact with the C16orf78 cysteine residue. These inhibitors have been shown to inhibit the activity of histone-modifying enzymes, including histone acetyltransferases (HATs) and histone-remodeling enzymes. These inhibitors have the potential to treat various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Biomarker Potential

C16orf78 has also been identified as a potential biomarker for various diseases. The C16orf78 gene has been shown to be highly expressed in various tissues and fluids, including cancer cells, neurodegenerative disorders, and autoimmune diseases.

In addition, several studies have shown that C16orf78 can be used as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, a study by Xu et al. (5) found that C16orf78 was highly expressed in various tissues of neuroblastoma, a type of cancer that affects the neural stem cells that develop into muscles, bones, and other tissues.

Conclusion

C16orf78 is a gene located within the ORF 78 region of chromosome 16 that has been identified as a potential drug target due to its unique farnesylated cysteine residue. The C16orf78 gene has also been shown to be highly conserved across various species and has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Future studies are needed to further investigate the potential of C16orf78 as a drug target and biomarker. More research is needed to identify small molecule inhibitors that can interact with the C16orf78 cysteine residue and to develop biomarkers for various diseases associated with this gene.

Protein Name: Chromosome 16 Open Reading Frame 78

The "C16orf78 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C16orf78 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets